Journal of Biological Chemistry · 2003 · 176 citations · 30 references
Life SciencesBiochemistryPharmacologyGene ExpressionMetabolismMolecular PharmacologyEnzyme InductionHepatic MetabolismHepatotoxicity MechanismsXenobiotic MetabolismAh Receptor-mediated InductionConstitutive Receptor ActivityInduction In HepatocytesMetabolic Enzyme InductionUdp-glucuronosyltransferase ActivityXenobiotic Receptor ActivationXenobiotic-induced Gene Expression
UDP-glucuronosyltransferase 1A1 (UGT1A1) plays an important physiological role by contributing to the metabolism of endogenous substances such as bilirubin in addition to xenobiotics and drugs. The UGT1A1 gene has been shown to be inducible by nuclear receptors steroid xenobiotic receptor (SXR) and the constitutive active receptor, CAR. In this report, we show that in human hepatoma HepG2 cells the UGT1A1 gene is also inducible with aryl hydrocarbon receptor (Ah receptor) ligands such as 2,3,7,8-tetrachlodibenzo-p-dioxin (TCDD), β-naphthoflavone, and benzo[a]pyrene metabolites. Induction was monitored by increases in protein and catalytic activity as well as UGT1A1 mRNA. To examine the molecular interactions that controlUGT1A1 expression, the gene was characterized and induction by Ah receptor ligands was regionalized to bases −3338 to −3287. Nucleotide sequence analysis of this UGT1A1 enhancer region revealed a xenobiotic response element (XRE) at −3381/−3299. The dependence of the XRE on UGT1A1-luciferase activity was demonstrated by a loss of Ah receptor ligand inducibility when the XRE core region (CACGCA) was deleted or mutated. Gel mobility shift analysis confirmed that TCDD induction of nuclear proteins specifically bound to the UGT1A1-XRE, and competition experiments with Ah receptor and Arnt antibodies demonstrated that the nuclear protein was the Ah receptor. These observations reveal that the Ah receptor is involved in human UGT1A1 induction. UDP-glucuronosyltransferase 1A1 (UGT1A1) plays an important physiological role by contributing to the metabolism of endogenous substances such as bilirubin in addition to xenobiotics and drugs. The UGT1A1 gene has been shown to be inducible by nuclear receptors steroid xenobiotic receptor (SXR) and the constitutive active receptor, CAR. In this report, we show that in human hepatoma HepG2 cells the UGT1A1 gene is also inducible with aryl hydrocarbon receptor (Ah receptor) ligands such as 2,3,7,8-tetrachlodibenzo-p-dioxin (TCDD), β-naphthoflavone, and benzo[a]pyrene metabolites. Induction was monitored by increases in protein and catalytic activity as well as UGT1A1 mRNA. To examine the molecular interactions that controlUGT1A1 expression, the gene was characterized and induction by Ah receptor ligands was regionalized to bases −3338 to −3287. Nucleotide sequence analysis of this UGT1A1 enhancer region revealed a xenobiotic response element (XRE) at −3381/−3299. The dependence of the XRE on UGT1A1-luciferase activity was demonstrated by a loss of Ah receptor ligand inducibility when the XRE core region (CACGCA) was deleted or mutated. Gel mobility shift analysis confirmed that TCDD induction of nuclear proteins specifically bound to the UGT1A1-XRE, and competition experiments with Ah receptor and Arnt antibodies demonstrated that the nuclear protein was the Ah receptor. These observations reveal that the Ah receptor is involved in human UGT1A1 induction. glucuronosyltransferase 2,3,7,8-tetrachlodibenzo-p-dioxin constitutive active receptor steroid xenobiotic receptor β-naphthoflavone benzo[a]pyrene N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine dithiothreitol xenobiotic response element drug response element Glucuronidation has evolved in vertebrates to catalyze the transfer of glucuronic acid from uridine 5′-diphosphoglucuronic acid to soluble non-lipid dependent substances generated as byproducts of dietary and cellular metabolism (1Dutton G.J. Glucuronidation of Drugs and Other Compounds. CRC Press, Inc., Boca Raton, FL1980Google Scholar). Some of the endogenous agents that are targets for glucuronidation are bilirubin and many of the steroids as well as several phenolic neurotransmitters. In addition, hundreds of drugs and xenobiotics are subject to glucuronidation (2Miners J.O. Mackenzie P.I. Pharmacol. Ther. 1991; 51: 347-369Crossref PubMed Scopus (330) Google Scholar, 3Tukey R.H. Strassburg C.P. Annu. Rev. Pharmacol. Toxicol. 2000; 40: 581-616Crossref PubMed Scopus (1299) Google Scholar). The vast numbers of endogenous and exogenous substances that are susceptible to glucuronidation in humans are catalyzed by the family of UDP-glucuronosyltransferases (UGTs).1 A comparison of the deduced amino acid sequence of the UGTs in mammalian species has helped in classifying these proteins as members of the UGT1 or UGT2 gene family (4Mackenzie P.I. Owens I.S. Burchell B. Bock K.W. Bairoch A. Belanger A. Fournel-Gigleux S. Green M. Hum D.W. Iyanagi T. Lancet D. Louisot P. Magdalou J. Chowdhury Ritter Jr., J.K. Schachter H. Tephly T.R. Tipton K.F. Nebert D.W. Pharmacogenetics. 1997; 7: 255-269Crossref PubMed Scopus (1007) Google Scholar). In humans, 16 cDNAs have been identified and shown through expression experiments in tissue culture to encode proteins that display functional glucuronidation activity (3Tukey R.H. Strassburg C.P. Annu. Rev. Pharmacol. Toxicol. 2000; 40: 581-616Crossref PubMed Scopus (1299) Google Scholar). It is generally felt that evolutionary constraints associated with the UGT1 family of proteins leads to more efficient glucuronidation of drugs and xenobiotics, whereas the UGT2 family of proteins displays far greater catalytic diversity toward endogenous agents such as steroids. Regulation of the UGTs in human tissues is tightly controlled. Analysis of RNA expression patterns has demonstrated that no two tissues display the same pattern of UGT gene expression, indicating that regulatory control occurs in a tissue-specific manner (5Tukey R.H. Strassburg C.P. Mol. Pharmacol. 2001; 59: 405-414Crossref PubMed Scopus (211) Google Scholar). In addition, environmental influences on gene control clearly indicate that the UGTs are capable of undergoing differential regulation resulting in enhanced glucuronidation capacity. The treatment of Caco-2 cells with the antioxidant tert-butylhydroquinone leads to induction of UGT1A6, UGT1A9, and UGT2B7 (6Munzel P.A. Schmohl S. Heel H. Kalberer K. Bock-Hennig B.S. Bock K.W. Drug Metab. Dispos. 1999; 27: 569-573PubMed Google Scholar, 7Bock K.W. Eckle T. Ouzzine M. Fournel-Gigleux S. Biochem. Pharmacol. 2000; 59: 467-470Crossref PubMed Scopus (74) Google Scholar). Transcriptional regulation ofUGT1A6 and UGT1A9 occurs after exposure to Ah receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (6Munzel P.A. Schmohl S. Heel H. Kalberer K. Bock-Hennig B.S. Bock K.W. Drug Metab. Dispos. 1999; 27: 569-573PubMed Google Scholar, 8Munzel P.A. Lehmkoster T. Bruck M. Ritter J.K. Bock K.W. Arch. Biochem. Biophys. 1998; 350: 72-78Crossref PubMed Scopus (56) Google Scholar). Human UGT1A1 has recently been shown to be under control by agents that induce gene expression in concordance with the constitutive active receptor (CAR) (9Sugatani J. Kojima H. Ueda A. Kakizaki S. Yoshinari K. Gong Q.H. Owens I.S. Negishi M. Sueyoshi T. Hepatology. 2001; 33: 1232-1238Crossref PubMed Scopus (332) Google Scholar) and the steroid xenobiotic receptor (SXR) (33Xie W. Yeuh M.-F. Radominska-Pandya A. Saini S.P.S. Negishi Y. Bottroff B.S. Cabrera G.Y. Tukey R.H. Evan R.M. Proc. Natl. Acad. Sci. U. S. A. 2003; (in press)Google Scholar). The treatment of HepG2 and Caco-2 cells with the flavonoid chrysin leads to the induction of UGT1A1 (10Walle T. Otake Y. Galijatovic A. Ritter J.K. Walle U.K. Drug Metab. Dispos. 2000; 28: 1077-1082PubMed Google Scholar, 11Galijatovic A. Otake Y. Walle U.K. Walle T. Pharmacol. Res. 2001; 18: 374-379Crossref Scopus (103) Google Scholar, 12Galijatovic A. Walle U.K. Walle T. Pharmacol. Res. 2000; 17: 21-26Crossref Scopus (88) Google Scholar). Interestingly, flavonoids have also been shown to induceCYP1A1 (13Allen S.W. Mueller L. Williams S.N. Quattrochi L.C. Raucy J. Drug Metab. Dispos. 2001; 29: 1074-1079PubMed Google Scholar) in a CYP1A1-luciferase reporter HepG2 cell line (14Postlind H. Vu T.P. Tukey R.H. Quattrochi L.C. Toxicol. Appl. Pharmacol. 1993; 118: 255-262Crossref PubMed Scopus (138) Google Scholar), implicating a potential role for the induction ofUGT1A1 through a similar mechanism. One potential mechanism that may link the expression of UGT1A1 and CYP1A1by flavonoids is the ability of these agents to activate the Ah receptor. Although the mechanisms surrounding expression ofCYP1A1 after activation of the Ah receptor are well documented (15Gu Y.Z. Hogenesch J.B. Bradfield C.A. Annu. Rev. Pharmacol. Toxicol. 2000; 40: 519-561Crossref PubMed Scopus (857) Google Scholar, 16Denison M.S. Whitlock Jr., J.P. J. Biol. Chem. 1995; 270: 18175-18178Abstract Full Text Full Text PDF PubMed Scopus (332) Google Scholar, 17Whitlock J.P.J. Chichester C.H. Bedgood R.M. Okino S.T. Ko H.P. Ma Q. Dong L. Li H. Clarke-Katzenberg R. Drug Metab. Rev. 1997; 29: 1107-1127Crossref PubMed Scopus (65) Google Scholar), there is little information linking expression of the human UGT1A1 gene through an Ah receptor-dependent mechanism. Experiments were undertaken in this study to examine the actions of several Ah receptor ligands to modulate expression of the UGT1A1 gene. 1-Naphthol, 17α-ethynylestradiol,o-nitrophenyl-β-d-galactopyranoside and β-naphthoflavone (BNF) were purchased from Sigma. TCDD, 1-hydroxybenzo[a]pyrene (1B[a]P), 2B[a]P, 3B[a]P, 4B[a]P, 6B[a]P, 7B[a]P, 8B[a]P, 9–9B[a]P, 10B[a]P, benzo[a]pyrene-cis-4,5-dihydrodiol, and benzo[a]pyrene-trans-4,5-dihydrodiol were obtained from the National Cancer Institute, National Institutes of Health, Chemical Carcinogen Reference Standard Repository (Kansas City, MO). The Bio-Rad protein assay for protein concentration analysis was purchased from Bio-Rad. Restriction enzymes and T4 ligase were from New England Biolabs (Beverly, MA). Taq polymerase and the reporter plasmids PGL3-basic vector and PGL3-promoter vector were from Promega(Madison, WI). Custom oligonucleotides used in PCR cloning, DNA sequencing, and electrophoretic mobility shift assay were purchased from Genbase (San Diego, CA). The β-galactosidase expression vector PCMVβ Gal was purchased from Clontech (Palo Alto, CA). Thin-layer chromatography plates for enzyme analysis were from Whatman (Clifton, NJ). The human cell lines used in this study are the hepatoma-derived HepG2 and the human CYP1A1-luciferase reporter gene TV101 cell line (14Postlind H. Vu T.P. Tukey R.H. Quattrochi L.C. Toxicol. Appl. Pharmacol. 1993; 118: 255-262Crossref PubMed Scopus (138) Google Scholar). Both cell lines were maintained at 37 °C in 95% air and 5% CO2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Cells were trypsinized 24 h before chemical treatment, and 106cells were seeded in P100 plates. Cells were treated for 24–72 h with either TCDD (10 nm) or BNF (20 μm). For transient transfection experiments, 105 cells were split into 12-well plates ∼24 h before transfection followed by chemical treatment for 48 h. Chemicals were first dissolved in Me2SO, and Me2SO concentration in media never exceeded 0.1% (v/v). Fresh media and chemical treatment were changed every 24 h. UDP-glucuronosyltransferase analysis was determined using 1-naphthol and 17α-ethynylestradiol as substrates (18Bansal S.K. Gessner T. Anal. Biochem. 1980; 109: 321-329Crossref PubMed Scopus (133) Google Scholar). HepG2 cells were treated with either 10 nm TCDD or 20 μm BNF, and the cells were collected after 24–72 h of treatment. Whole cell lysates were prepared. Each UGT assay was conducted in a total volume of 100 μl containing 50 mmTris-HCl, pH 7.6, 10 μm uridine 5′-diphosphoglucuronic of 5′-diphosphoglucuronic acid 100 μm and 100 of Each was at 37 °C for plates were with a were and by HepG2 cells were collected and in and in of The cells were on a for at with a Each was first for at in a followed by for 10 at was at in a and the were in were on 10% as by the (10 was at for 50 and at for h to The was with 5% in for h at followed by with UGT1A1 J.K. Hepatology. 1999; PubMed Scopus Google Scholar) or P. 1995; PubMed Scopus Google Scholar) in at The were and treated with or for h at of the proteins was conducted by HepG2 cells were treated for 24–72 h with 10 nm TCDD or 20 μm BNF, and total RNA was using For of total RNA was through RNA was by the was with to RNA for A by the UGT1A1 was by and using a the was to and with the at °C for h followed by in and and 0.1% at °C for was using a containing were characterized by a human DNA as well as a UGT1A1 containing the were by PCR using to on the as in Q.H. T. S. S. Owens I.S. Pharmacogenetics. 2001; PubMed Scopus Google Scholar). The in is at as characterized J.K. S. Owens I.S. J. Biol. Chem. Full Text PDF PubMed Google Scholar). The enzyme and were at the of the and The PCR for the UGT1A1 was generated with oligonucleotides and are in and and into PGL3-basic was identified as the in the (14Postlind H. Vu T.P. Tukey R.H. Quattrochi L.C. Toxicol. Appl. Pharmacol. 1993; 118: 255-262Crossref PubMed Scopus (138) Google Scholar), the gene was and into the of the The of the used for the are as and and and and and and Each of these were with and into PGL3-promoter For of the enhancer was used as The used for of the were and The two that the were and The region the of the Ah receptor core and the and bases are that were changed the XRE sequence to the Ah receptor region of the sequence and the was into these same in the PGL3-promoter HepG2 cells were in 12-well tissue culture plates at and after 24 h using as by the In transfection of and of β-galactosidase expression vector as an control to for transfection The after the cells were treated with 20 μm BNF, 10 or Me2SO for 48 h. The cells were and for and β-galactosidase were by the Tukey R.H. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar) using a HepG2 cells were in and lysates were and 10 μl of the was with μl of pH and were by 100 μl of dissolved in pH was for 10 and the activity is as were determined using a assay from the of experiments in or HepG2 cells that were seeded at tissue culture the was as 48 h of the cells were volume of the collected cells was into a tissue culture and the cells were to media containing of cells were and in plates with A of was and was and treated with μm TCDD for 24 h followed by analysis of For these the cell line is to as from HepG2 cells were as Tukey R.H. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar), with of the at 48 h of treatment with 10 nm TCDD, 20 μm BNF, or Me2SO, HepG2 cells were with 10 pH collected by into pH and with a tissue by an The was at for and the was with pH The was in pH and at for and the was as nuclear A of and the core sequence of the UGT1A1 XRE element were For analysis of Ah receptor the oligonucleotides and were used as Tukey R.H. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). oligonucleotides were by of either the XRE or and with in the of and μm and were on containing of 10 of nuclear of and of DNA in a volume of μl containing pH 10% Tukey R.H. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). To examine the of Ah receptor 100 of receptor or from was in the was on a using 10 as a were by a of or UGT1A1 XRE The were and were by a Human TV101 cells were from the human hepatoma cell line HepG2 the to the gene (14Postlind H. Vu T.P. Tukey R.H. Quattrochi L.C. Toxicol. Appl. Pharmacol. 1993; 118: 255-262Crossref PubMed Scopus (138) Google Scholar). The of the Ah XRE activity from Ah receptor activation after treatment with Ah receptor The TV101 cells were under the same as HepG2 cells supplemented with The TV101 cells were treated with TCDD, BNF, or Me2SO at to ability to activate gene activity was and for protein The phenolic 1-naphthol was used as a to examine UGT activity in HepG2 cells of HepG2 cells with 10 nm TCDD for h to a in 1-naphthol UGT activity that was determined to be treatment of cells with 20 μm BNF in a in 1-naphthol UGT have been shown to be by of the proteins (3Tukey R.H. Strassburg C.P. Annu. Rev. Pharmacol. Toxicol. 2000; 40: 581-616Crossref PubMed Scopus (1299) Google Scholar), with a for UGT1A6, and Glucuronidation of a that is by was in or cells ofUGT1A1 RNA by analysis demonstrated that TCDD and BNF UGT1A1 in a greater increases in RNA were with a pattern that was also in catalytic It was also that induction of UGT1A1 RNA and 17α-ethynylestradiol glucuronidation by TCDD and BNF with of UGT1A1 protein with BNF greater of UGT1A1 in In HepG2 TCDD and BNF are capable of as shown by induction of and activation of the gene in TV101 cells Induction in TV101 cells has been to activation of the Ah receptor Tukey R.H. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, L.C. Tukey R.H. Mol. Pharmacol. 1993; Google Scholar). Although activity is h in TV101 cells with TCDD and BNF, of UGT1A1 RNA and protein are at 48 h indicating that regulatory may control the UGT1A1 these indicate that induction of UGT1A1 may through an Ah receptor-dependent of TCDD and BNF were for ability to induce activity in HepG2 TV101 cells at after treatment. activity was as of The at the of two To examine the mechanism of UGT1A1 an region of the UGT1A1 was from a human containing the UGT1A1 and enhancer by were into the or of the regulatory region the a from to whereas the enhancer bases from and Each was into HepG2 and expression of activity was determined after treatment of cells for 48 h with TCDD or BNF of 48 h for the treatment was we of RNA and protein in HepG2 The UGT1A1 was after treatment with TCDD and enhancer sequence from to to the was also and a region from to were to TCDD and Induction of the with TCDD that the activation may through an Ah receptor-dependent mechanism. that have been shown to be ligands for the Ah receptor are To examine this we cells the UGT1A1-luciferase and demonstrated that of benzo[a]pyrene were capable of and of benzo[a]pyrene in addition to and benzo[a]pyrene with TCDD we a induction of activity with the and and as the efficient The of cell lines in Ah receptor show that induce gene expression in an Ah receptor-dependent M. R. S. Arch. Biochem. Biophys. PubMed Scopus Google Scholar). It has also been demonstrated through the of reporter gene that are by the Ah receptor enhancer sequence that induce through activation of the Ah receptor (14Postlind H. Vu T.P. Tukey R.H. Quattrochi L.C. Toxicol. Appl. Pharmacol. 1993; 118: 255-262Crossref PubMed Scopus (138) Google Scholar, J. S. B. J. D. Vu T. Tukey R.H. Res. 1999; Scopus Google Scholar, M.S. Toxicol. Chem. PubMed Scopus Google Scholar). the of TCDD, BNF, and induction of the UGT1A1 that these agents activation through and Ah receptor-dependent To the region on the UGT1A1 gene that analysis on the demonstrated that a in induction was bases −3338 and analysis in this region revealed the of a of the Ah receptor XRE (CACGCA) at DNA to was on the XRE to transfection of this demonstrated that the in a loss of inducibility by TCDD and Regulation of UGT1A1 by the XRE core sequence that the may be a for the Ah receptor. of Ah receptor to the XRE response element in region was by mobility shift analysis nuclear from HepG2 cells was with an was for the XRE was when as well was in the A similar of experiments were conducted using the as of a nuclear protein to the be when the were conducted in the of To the nuclear protein that with the UGT1A1 XRE is the Ah receptor, mobility shift analysis experiments were in the of antibodies toward the Ah receptor and of the nuclear protein to the sequence was by the and Arnt was when the were with a UGT Full Text PDF PubMed Google Scholar), that the of by the Ah receptor and Arnt antibodies was a control to the of the antibodies in the functional Ah receptor, a similar was using as The Ah receptor and Arnt antibodies of the nuclear protein to the these experiments that the induction of UGT1A1 by TCDD is in by of the Ah to The human UGT1A1 gene plays an important role in by as the for the glucuronidation of bilirubin J. B. Chowdhury Chowdhury J. Biol. Chem. Full Text PDF PubMed Google Scholar), the of The gene is in a tissue-specific in humans C.P. Tukey R.H. Mol. Pharmacol. 1998; Google Scholar, C.P. Strassburg A. Li Q. Tukey R.H. Biochem. J. 1999; PubMed Scopus Google Scholar, C.P. S. J. P. A. Tukey R.H. J. Biol. Chem. 2000; Full Text Full Text PDF Scopus Google Scholar), indicating that regulatory are involved also be by environmental of HepG2 (10Walle T. Otake Y. Galijatovic A. Ritter J.K. Walle U.K. Drug Metab. Dispos. 2000; 28: 1077-1082PubMed Google Scholar) and Caco-2 Cells A. Otake Y. Walle U.K. Walle T. Pharmacol. Res. 2001; 18: 374-379Crossref Scopus (103) Google Scholar) by (10Walle T. Otake Y. Galijatovic A. Ritter J.K. Walle U.K. Drug Metab. Dispos. 2000; 28: 1077-1082PubMed Google Scholar, U.K. Walle T. Drug Metab. Dispos. PubMed Scopus Google Scholar) In human treatment with and to the induction of UGT1A1 and protein J.K. Hepatology. 1999; PubMed Scopus Google Scholar). The the human UGT1A1 gene through at a nuclear receptor sequence bases in has recently identified a human in this same region (33Xie W. Yeuh M.-F. Radominska-Pandya A. Saini S.P.S. Negishi Y. Bottroff B.S. Cabrera G.Y. Tukey R.H. Evan R.M. Proc. Natl. Acad. Sci. U. S. A. 2003; (in press)Google Scholar). These that gene differential regulation of tissue-specific expression and inducibility with drugs and In addition to these we have demonstrated that gene is also by the human Ah receptor in response to TCDD, BNF, and metabolites. HepG2 cells to TCDD and BNF as shown by analysis and by an in 17α-ethynylestradiol UGT The Ah receptor is functional in these cells as from the induction of protein as well as regulation of have a regulatory sequence on the UGT1A1 gene that an XRE core is in to the (9Sugatani J. Kojima H. Ueda A. Kakizaki S. Yoshinari K. Gong Q.H. Owens I.S. Negishi M. Sueyoshi T. Hepatology. 2001; 33: 1232-1238Crossref PubMed Scopus (332) Google Scholar) and bases containing the Ah receptor sequence with the nuclear Ah receptor in HepG2 of this sequence of the Ah receptor, whereas the of enhancer containing the same leads to a loss of TCDD and BNF induction of reporter gene It that this element plays an important role in regulation of exposure to TCDD and The of the that Ah receptor ligands may UGT1A1 in a with with that we have for TCDD and BNF, such as of are capable of In addition, there is that of the flavonoids modulate gene regulation in through the Ah receptor. is a of UGT1A1 (10Walle T. Otake Y. Galijatovic A. Ritter J.K. Walle U.K. Drug Metab. Dispos. 2000; 28: 1077-1082PubMed Google Scholar) and is to induce the expression as demonstrated through induction in TV101 Galijatovic and R. H. in show that Ah receptor ligands such as are capable of B. A. S. Strassburg C.P. P. Arch. Biochem. Biophys. 2000; PubMed Scopus Google Scholar), and is well that is a Ah receptor a used in the treatment of the Ah receptor and L.C. Tukey R.H. Mol. Pharmacol. 1993; Google Scholar). Although induction of has been shown to UGT activity greater K. Pharmacol. Ther. 1995; PubMed Scopus Google Scholar). UGT1A1 is in the C.P. S. J. P. A. Tukey R.H. J. Biol. Chem. 2000; Full Text Full Text PDF Scopus Google Scholar). is important to that regulation of UGT1A1 and may a flavonoid that is a of human UGT1A1 U.K. Walle T. Drug Metab. Dispos. PubMed Scopus Google Scholar), has to induce as by induction of CYP1A1-luciferase in TV101 cells (13Allen S.W. Mueller L. Williams S.N. Quattrochi L.C. Raucy J. Drug Metab. Dispos. 2001; 29: 1074-1079PubMed Google Scholar). may UGT1A1 in a manner that is of the Ah receptor. by (9Sugatani J. Kojima H. Ueda A. Kakizaki S. Yoshinari K. Gong Q.H. Owens I.S. Negishi M. Sueyoshi T. Hepatology. 2001; 33: 1232-1238Crossref PubMed Scopus (332) Google Scholar) and by these and (33Xie W. Yeuh M.-F. Radominska-Pandya A. Saini S.P.S. Negishi Y. Bottroff B.S. Cabrera G.Y. Tukey R.H. Evan R.M. Proc. Natl. Acad. Sci. U. S. A. 2003; (in press)Google Scholar), the UGT1A1 gene be by ligands that activate nuclear receptors and the Ah receptor. These regulatory are a region on the UGT1A1 gene bases and The of these xenobiotic receptors in to may an important role in expression and are of the nuclear receptors that are to nuclear It has been that the xenobiotic nuclear receptors a family of regulatory proteins that are involved in steroid and xenobiotic to gene expression patterns for B. Jr., W. H. Jr., J. R.M. 1998; PubMed Scopus Google Scholar, Mol. 2000; PubMed Scopus Google Scholar). to these nuclear receptors are to a of and xenobiotic Although of the nuclear receptor the Ah receptor also to modulate and enzymes in response to environmental regulation ofUGT1A1 be by endogenous agents that are ligands for and as well as xenobiotics that are ligands for and the Ah receptor. of and for a of the and of for a of the for Cancer of of the receptor and and H. of The a of the
30
SXR, a novel steroid and xenobioticsensing nuclear receptor
Bruce Blumberg, Walid Sabbagh, Henry Juguilon et al. · Genes & Development · 1998 · 920 citations · Full text
Joseph K. Ritter, Fei Chen, Yhun Yhong Sheen et al. · Journal of Biological Chemistry · 1992 · 478 citations · Full text